NANO NEUROSCIENCES

NEWSLETTER Vol. III / 21 July 25

2025
A Year of Innovation Paving the Way for the Future of **Glaucoma Care**

As we closed Q2 2025, we reflect with pride on the remarkable journey we've continued at NanoNeurosciences Inc. Since our April newsletter, our team has been diligently transforming our bold vision into tangible progress, reaching key milestones that advance our mission to pioneer transformative, non-invasive therapeutics for glaucoma and neurodegenerative diseases. From scientific breakthroughs to strengthened partnerships, this quarter has laid a solid foundation for our next phase of growth and impact.

UF Innovate | Accelerate at Sid Martin Biotech Incubator, Alachua, Florida (R&D Laboratories)



Fostering Strong Connections with Local and Global Biotech Ecosystems

NanoNeurosciences, Inc. participated in various events in the 2nd quarter of 2025.

ARVO 2025
May 4 – 8
Salt Lake City, Utah

ARVO Association for Research in Vision and Ophthalmology (ARVO) took place May 4-8, in Salt Lake City, USA.



2025 Early Stage Venture Conference from Florida Venture Forum

Scientific Milestones

Our research team has made significant strides in the quarter of 2025

Automated Peptide Synthesizer – Delivered and operational; initial evaluation of newly synthesized lipopeptides is underway (CEM Liberty PRIME 2.0) with the RAZOR (Automated cleavage system). The Liberty PRIME™ 2.0 is an ultra-efficient microwave peptide synthesizer, delivering high-quality peptides with record-low waste generation and synthesis time.

The integration of this synthesis platform not only strengthens our R&D infrastructure but also lays a robust foundation for future GMP-compliant scale-up and preclinical formulation batches. This milestone marks a pivotal step in our journey toward translating our nanomedicine innovations into therapeutic products for glaucoma and neurodegenerative diseases.

Biochemical Validation of the Final Candidates

We have successfully completed biochemical assessments, selecting our lead therapeutic candidates, which are now prepared for subsequent efficacy studies.

Following rigorous formulation, characterizatio, and in vitro evaluation, we have successfully identified and finalized our lead nanocarrier candidates.

These optimized formulations demonstrated superior stability and bioactivity profiles, meeting our predefined benchmarks for advancement.



Intravitreal (IVT) and Topical Biodistribution Experiments

To evaluate the ocular distribution and retention of our nanocarrier candidates, the selected formulations have been functionalized with a chromophore for tracking purposes.

These labeled nanostructures will be shipped to Pharmaseed Ltd. by the end of July for comprehensive biodistribution studies via both intravitreal and topical administration.

These experiments will provide critical insight into the in vivo behavior, localization, and clearance of our candidates, supporting further optimization and preclinical validation.

Efficacy Validation Studies

The final candidates will be shipped by the end of August to Iris Pharma for **in vivo testing** to support our preclinical scientific claims. The selected candidates are now being prepared for shipment to our contract research partners for in vivo efficacy testing. This marks a significant milestone in our development pipeline, as we transition from exploratory research to preclinical validation. The upcoming studies will assess the therapeutic potential of our intranasal formulations in relevant animal models for glaucoma, providing essential data to support our translational and regulatory path forward.

Strategic Partnerships & Business Achievements

To accelerate progress and maximize impact, **NanoNeuro sciences Inc.** has forged strategic partnerships with key industry leaders, spanning research institutions, device innovators, and contract research organizations (CROs). These collaborations are crucial in transforming cutting-edge science into real-world therapeutic solutions, bringing innovative nanomedicine technologies closer to the patients who need them most.

Efficacy Study Collaboration

We are deepening our partnership with Iris Pharma, a leading CRO specializing in ophthalmic research, to conduct critical efficacy studies supporting our preclinical development efforts.

Histology and Translational Research Partnership

We are proud to collaborate with **Pharmaseed Ltd.**, a certified preclinical CRO renowned for its expertise in translational research. Pharmaseed's multidisciplinary capabilities and "end-in-mind" approach enable us to perform complex studies, including advanced histological analyses, to assess the performance of our novel nanomedicine candidates.

Alongside our R&D progress, we've also achieved major business milestones this quarter, including:

Department of Defense (CDMRP) Grant Submitted

Federal Funding Opportunities

We secured invitations to submit full proposals for highly competitive federal funding programs, including the Congressionally Directed Medical Research Programs (CDMRP). Our full proposal was successfully submitted on July 21st.

Upcoming NSF SBIR Proposal

We are preparing to submit our NSF Small Business Innovation Research (SBIR) proposal in early September, following an invitation to advance to the full application stage.

New Website Launch

We're thrilled to announce the official launch of our new website on July 21st!

Visit **www.nanoneurosciences.com** to explore our mission, innovative technologies, and vision for the future. The site offers fresh insights into our intranasal nanocarrier platform and provides updates on our journey to advance precision treatments for glaucoma and neurodege-nerative diseases.

Investor and Sponsor Engagement

We continue to actively engage with potential sponsors and investors to support the scale-up of our technology and the transition into clinical development. Further engaging with potential sponsors and investors to support scale-up and clinical transition.

NanoNeurosciences Inc. Accepted into the NVIDIA Inception Program

We are proud to announce that **NanoNeurosciences Inc. has been officially accepted into the NVIDIA Inception Program.** This elite acceleration platform supports cutting-edge startups revolutionizing their industries through advanced technologies.

As part of this program, we gain access to technical resources, preferred pricing, and go-to-market support that will accelerate the integration of AI-driven design and modeling tools into our nanomedicine pipeline. This strategic partnership with NVIDIA strengthens our computational capabilities in nanocarrier optimization, predictive formulation, and targeted drug delivery, further reinforcing our mission to deliver precision therapeutics for glaucoma and neurodegenerative diseases.

Looking Ahead with Optimism and Purpose

NANO NEUROSCIENCES

NVIDIA Inception Program

As we progress through this transformative year, we do so with resolute optimism and determination.

Together, we've laid a strong foundation to advance breakthroughs in nanomedicine, with a particular focus on improving the lives of patients affected by open-angle glaucoma.

We are deeply grateful for your continued trust and support. It is this shared commitment that fuels our drive to push the boundaries of science and deliver innovative, life-changing solutions to patients worldwide.

Your collaboration and support inspire and drive us forward!
The NanoNeurosciences Team

NANO
NEUROSCIENCES

info@nanoneurosciences.com

NanoNeurosciences Research & Development Laboratory:
UF Innovate at Sid Martin, 12085 Research Dr, Lab #130, Alachua, FL 32615, USA
www.nanoneurosciences.com